Tech Company Financing Transactions
Anocca Funding Round
Anocca, based in Södertälje, secured $26.6 million in funding from European Investment Bank.
Transaction Overview
Company Name
Announced On
12/21/2022
Transaction Type
Debt
Amount
$26,640,000
Round
Undisclosed
Investors
European Investment Bank (Lead Investor)
Proceeds Purpose
Our financing will help to accelerate clinical development to provide patients with access to innovative therapies in areas of high unmet medical need. This support confirms EIB's role as a leading investor in innovation and life sciences and boosts Europe's competitiveness and role as a research powerhouse
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Forskargatan 20C
Södertälje, 151 36
SE
Södertälje, 151 36
SE
Phone
Website
Email Address
Overview
Anocca is a privately held Swedish biotechnology company founded in 2014 with the mission to establish a unique technology platform for analysis of T-cell biology to unlock the therapeutic potential of T-cell immunity. Anocca's technologies enable the highly precise and efficient analysis of T-cell biology required to deliver a range of therapeutics that specifically harness or manipulate T-cell immunity in a number of disease areas. With a focus on delivering TCR-modified T-cell therapies (TCR-T) in oncology, Anocca is rapidly progressing a pipeline of novel T-cell therapies towards clinical trials utilizing our own manufacturing capabilities.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 12/21/2022: Fiscozen venture capital transaction
Next: 12/21/2022: Treblle venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs